XingImaging said this will expand the company's capabilities and scope in neuroscience and oncology.

The proposed collaboration is subject to customary closing conditions. This includes approval by regulatory agencies. The companies expect the transaction to close by mid-2023. Chestnut Partners, Inc. is acting as exclusive financial advisor to XingImaging for this transaction.